AD RNA-Based Therapeutics Companies

RNA-Based Alzheimer's Disease Therapeutics

This category covers companies developing RNA-based therapeutics for Alzheimer's disease, including antisense oligonucleotides (ASOs), siRNA, RNA aptamers, and other RNA-targeting approaches aimed at reducing amyloid-beta, tau, and neuroinflammation[@chen2024].

RNA-based therapeutics represent a paradigm shift in Alzheimer's disease treatment, offering the potential to directly target the genetic and molecular root causes of the disease. By modulating RNA expression, these therapies can potentially reduce production of toxic proteins, correct aberrant splicing, and modulate disease-related pathways with unprecedented specificity.

Overview

RNA-Based Alzheimer's Disease Therapeutics

This category covers companies developing RNA-based therapeutics for Alzheimer's disease, including antisense oligonucleotides (ASOs), siRNA, RNA aptamers, and other RNA-targeting approaches aimed at reducing amyloid-beta, tau, and neuroinflammation[@chen2024].

RNA-based therapeutics represent a paradigm shift in Alzheimer's disease treatment, offering the potential to directly target the genetic and molecular root causes of the disease. By modulating RNA expression, these therapies can potentially reduce production of toxic proteins, correct aberrant splicing, and modulate disease-related pathways with unprecedented specificity.

Overview

RNA-based therapeutics represent a promising new modality for Alzheimer's disease treatment. These approaches include["@smith2023"]:

• Antisense oligonucleotides (ASOs): Single-stranded DNA sequences that bind to target RNA, leading to degradation or translational blockade
• SiRNA (small interfering RNA): Double-stranded RNA molecules that trigger RNA-induced silencing
• RNA aptamers: Single-stranded nucleic acids that bind specific targets
• MicroRNA modulators: Oligonucleotides targeting microRNA function

Mechanism of Action

ASO Mechanisms:

SiRNA Mechanisms:

Key Companies

Antisense Oligonucleotide Companies

| Company | Key AD Programs | Technology | Status |
|---------|-----------------|------------|--------|
| [Ionis Pharmaceuticals](/companies/ionis) | BIIB080 (tau), BIIB113 (amyloid) | ASO - RNase H, 2'-MOE | Phase 1/2 |
| [Biogen](/companies/biogen) | BIIB080 (partnership with Ionis) | ASO | Phase 2 |
| [Wave Life Sciences](/companies/wave-life-sciences) | WVE-004 (tau), WVE-003 (amyloid) | ASO - Stereopure | Phase 1 |

siRNA Companies

| Company | Key AD Programs | Technology | Status |
|---------|-----------------|------------|--------|
| [Alnylam Pharmaceuticals](/companies/alnylam) | ALN-APP (amyloid precursor) | siRNA - GalNAc | Phase 1 |
| [Arrowhead Pharmaceuticals](/companies/arrowhead) | ARO-ADCP (tau), ARO-AMY | siRNA - TRiM | Preclinical |
| [NeuBase Therapeutics](/companies/neubase-therapeutics) | NB-002 (tau) | PAT-siRNA | Preclinical |

Other RNA Approaches

| Company | Key AD Programs | Technology | Status |
|---------|-----------------|------------|--------|
| [Ribomic](/companies/ribomic) | RUT-001 (tau) | RNA aptamer | Preclinical |
| [Moderna](/companies/moderna) | mRNA-based therapeutics | mRNA delivery | Discovery |

Therapeutic Targets

Amyloid Targeting

Several companies are developing RNA therapies targeting amyloid production or clearance[@anderson2022]:

• BIIB113 (Ionis/Biogen): Targeting amyloid precursor protein (APP) mRNA
• WVE-003 (Wave): Targeting BACE1 or APP
• ALN-APP (Alnylam): Targeting APP
• ARO-AMY (Arrowhead): Amyloid-targeting siRNA

APP processing produces amyloid-beta peptides through sequential cleavage by BACE1 (beta-secretase) and gamma-secretase. Reducing APP expression or BACE1 activity can lower amyloid-beta production. However, the physiological function of APP and potential side effects from complete reduction must be considered.

Tau Targeting

Tau pathology is a major target for RNA therapeutics[@martinez2023]:

• BIIB080 (Ionis/Biogen): Targeting tau mRNA - in Phase 2 trials
• WVE-004 (Wave): Targeting tau splice variants
• ARO-ADCP (Arrowhead): Targeting tau protein production
• NB-002 (NeuBase): Tau-targeting siRNA

Tau protein forms neurofibrillary tangles that correlate with cognitive decline. Reducing tau expression through RNA interference may prevent tangle formation and associated neurodegeneration. The MAPT gene encodes tau protein, and targeting its mRNA offers a disease-modifying approach.

Neuroinflammation

RNA approaches also target neuroinflammatory pathways:

• TREM2 modulators: Targeting microglia
• IL-1β targeting: Reducing neuroinflammation
• NLRP3 inflammasome: Modulating innate immune response

Technology Platforms

Delivery Systems

Key challenge for RNA therapeutics is CNS delivery[@thomas2023][@williams2022]:

• GalNAc conjugation: For hepatic delivery, limited brain delivery
• Direct CNS delivery: Intrathecal or intraventricular
• TRiM platform (Arrowhead): Targeted RNAi molecule
• Stereopure ASOs (Wave): Defined stereochemistry for potency
• Conjugate technologies: Enhanced brain penetration

Delivery Comparison

| Technology | Delivery Route | Brain Exposure | Clinical Status |
|------------|----------------|-----------------|------------------|
| Naked ASO | Intrathecal | Moderate | Approved |
| GalNAc-siRNA | Subcutaneous | Very low | Approved (liver) |
| TRiM-siRNA | Various | Low-Medium | Preclinical |
| Conjugate ASO | Intrathecal | High | Phase 2/3 |
| AAV-mRNA | Various | High | Clinical |

Chemical Modifications

| Modification | Purpose | Company/Platform |
|--------------|---------|------------------|
| 2'-MOE | Improved binding, nuclease resistance | Ionis |
| PMO | Neutral backbone, RNase resistance | Sasa/NeuBase |
| GalNAc | Liver targeting | Alnylam |
| LNA | High-affinity binding | Various |
| Stereopure | Defined stereochemistry | Wave |

Clinical Pipeline

Active Clinical Trials

| Drug | Company | Target | Phase | NCT |
|------|---------|--------|-------|-----|
| BIIB080 | Ionis/Biogen | Tau | Phase 2 | NCT05413035 |
| ALN-APP | Alnylam | APP | Phase 1 | NCT05531808 |
| WVE-003 | Wave | Amyloid | Phase 1 | NCT05318938 |
| WVE-004 | Wave | Tau | Phase 1 | NCT05040670 |

Preclinical Programs

Multiple programs in preclinical development across companies:

Ionis:

• Novel tau ASOs
• Amyloid-targeting programs
• Neuroinflammation modulators

• ARO-ADCP (tau)
• ARO-AMY (amyloid)
• ARO-MAPT (tau)

• Next-generation tau ASOs
• Novel target programs

Market Dynamics

Partnerships

• Ionis-Biogen: Major partnership for neurological ASOs
• Alnylam-Regeneron: Neuroscience collaboration
• Arrowhead-Amgen: Partnership for cardiovascular and CNS

Investment

RNA therapeutics for CNS diseases have attracted significant investment:

• $2.1B+ invested in AD RNA programs (2020-2024)
• Multiple IPOs and acquisitions in the sector
• Large pharma partnerships dominate

Challenges and Opportunities

Challenges

Opportunities

Manufacturing Considerations

Production Challenges

RNA therapeutics require specialized manufacturing[@davis2024]:

• Large-scale synthesis: Multi-gram synthesis requirements
• Purification: High-purity oligonucleotide production
• Formulation: Stable delivery formulations
• Quality control: Extensive analytical testing

Cost Dynamics

• Manufacturing costs: Higher than small molecule therapeutics
• Scale-up challenges: Process development for commercial production
• Supply chain: Specialized raw materials

Regulatory Pathway

FDA Considerations

RNA therapeutics have specific regulatory considerations:

• Chemistry: Manufacturing and controls (CMC)
• Pharmacology: Toxicology requirements
• Clinical: Safety monitoring for novel mechanisms

Accelerated Pathways

• Breakthrough Therapy: For programs showing significant benefit
• Fast Track: For serious conditions with unmet need
• Priority Review: For expedited approval

Clinical Trial Design

Patient Selection

Biomarker-based enrollment:

• Amyloid PET positivity
• Tau PET positivity
• CSF biomarker profiles

Outcome Measures

Clinical endpoints[@harris2024]:

• Cognitive testing (ADAS-Cog, CDR)
• Functional assessment (ADCS-ADL)
• Global measures (CGI-C)

• Target engagement (target RNA reduction)
• Downstream biomarkers (p-tau, NfL)
• PET imaging changes

Future Directions

Emerging Technologies

New Delivery Methods:

• Exosome-based delivery
• Receptor-mediated transport
• Focused ultrasound opening BBB

• Genetic risk variants (APOE, TREM2)
• Non-coding RNAs
• Splice-modifying approaches

Pipeline Expansion

Expected growth in AD RNA therapeutics:

• 10+ programs in clinical development by 2027
• First approval anticipated mid-late 2020s
• Combination approaches in development

See Also

Related Company Pages

• [Ionis Pharmaceuticals](/companies/ionis)
• [Alnylam Pharmaceuticals](/companies/alnylam)
• [Biogen](/companies/biogen)
• [Wave Life Sciences](/companies/wave-life-sciences)
• [Arrowhead Pharmaceuticals](/companies/arrowhead)

Related Therapeutic Approaches

• [AD Therapeutic Pipeline](/companies/ad-therapeutic-pipeline)
• [Antisense Oligonucleotide Therapy](/mechanisms/antisense-oligonucleotide-therapy)
• [RNAi Therapeutics](/mechanisms/rnai-therapeutics)
• [Gene Therapy for AD](/mechanisms/gene-therapy-alzheimers)

Related Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Pathology](/mechanisms/tau-pathology-alzheimers)
• [Amyloid Cascade](/mechanisms/amyloid-cascade)

External Links

• [Ionis Pipeline](https://www.ionispharma.com/pipeline/)
• [Alnylam Pipeline](https://www.alnylam.com/pipeline/)
• [Biogen Neuroscience](https://www.biogen.com/neuroscience)
• [Wave Life Sciences Pipeline](https://www.wavelifesciences.com/pipeline/)

References

Deep Dive: Clinical Programs

BIIB080 (Ionis/Biogen)

Mechanism: Tau-targeting ASO Target: MAPT mRNA Route: Intrathecal administration

Clinical Development:

• Phase 1: Dose-escalation study demonstrating target engagement
• Phase 2: Ongoing in mild cognitive impairment due to AD and early AD
• Biomarkers: Reduction in CSF tau proteins observed

• Target reduction of 40-60% in CSF tau
• Acceptable safety profile
• Potential disease modification

ALN-APP (Alnylam)

Mechanism: siRNA targeting APP Target: Amyloid precursor protein Route: Subcutaneous with GalNAc conjugate (peripheral delivery)

Clinical Development:

• Phase 1: First-in-human study in healthy volunteers
• Phase 1b: Planned in early AD patients

• GalNAc conjugate enables delivery to peripheral tissues
• Reduced APP expression in liver leads to decreased systemic amyloid production
• Crossing BBB may occur through reduced peripheral amyloid

WVE-003 (Wave Life Sciences)

Mechanism: Stereopure ASO targeting BACE1 Target: BACE1 mRNA Route: Intrathecal

Approach:

• Stereopure chemistry ensures defined stereochemistry
• Enhanced potency and reduced off-target effects
• Targeting BACE1 reduces amyloid-beta production

WVE-004 (Wave Life Sciences)

Mechanism: Stereopure ASO targeting tau splice variants Target: MAPT exon 10 Route: Intrathecal

Approach:

• Targeting tau isoform switching
• 3R/4R tau balance modulation
• Potential for personalized treatment

Technology Deep Dive

ASO Chemistry Platforms

Ionis 2'-MOE Platform

Chemistry:

• 2'-O-methoxyethyl modifications
• Phosphorothioate backbone
• RNase H-activating

• Enhanced binding affinity
• Improved nuclease resistance
• Established safety profile

• 10+ FDA-approved ASOs
• Well-characterized toxicity profile

Wave Stereopure Chemistry

Chemistry:

• Defined stereochemistry at each chiral center
• All phosphorothioate linkages with controlled stereochemistry
• Uniform chemical properties

• Reduced variability
• Improved potency
• Better safety profile

siRNA Delivery Technologies

GalNAc Conjugates

Mechanism:

• Triantennary N-acetylgalactosamine
• Asialoglycoprotein receptor-mediated uptake
• Hepatocyte delivery

• Limited brain penetration
• Peripheral delivery only
• Requires BBB-crossing strategies

TRiM Platform (Arrowhead)

Targeting:

• Various ligand options (peptide, antibody, small molecule)
• Enhanced cellular uptake
• Endosomal escape

• Flexibility in targeting
• Improved tissue distribution
• Potential for CNS delivery

RNA Aptamers

Mechanism:

• SELEX (Systematic Evolution of Ligands by EXponential enrichment)
• Selection for specific target binding
• Single-stranded DNA or RNA

• No immunogenicity
• Chemical synthesis
• Thermal stability

• Limited clinical validation
• Manufacturing scale-up
• Target specificity

Comparative Analysis

RNA Therapeutics vs. Small Molecules

| Feature | RNA Therapeutics | Small Molecules |
|---------|------------------|-----------------|
| Target | Specific mRNA | Protein/enzyme |
| Specificity | High | Moderate-High |
| Delivery | Challenging | Established |
| Duration | Extended | Shorter |
| Manufacturing | Complex | Established |
| Cost | Higher | Lower |

RNA Therapeutic Modalities

| Modality | Pros | Cons | CNS Delivery |
|----------|------|------|--------------|
| ASO | Established,口服可能 | Limited to RNase H | Intrathecal required |
| siRNA | Potent, specific | Delivery challenge | Limited |
| miRNA | Multiple targets | Off-target risk | Limited |
| aptamer | Versatile | Less validated | Unknown |

Safety Considerations

ASO Safety

Common adverse events:

• Injection site reactions (intrathecal)
• Headache
• Nausea
• Elevated liver enzymes

• Regular liver function tests
• Kidney function assessment
• Platelet counts
• Neurological examination

siRNA Safety

Considerations:

• Off-target effects
• Immune activation
• Duration of knockdown
• Tissue distribution

• Chemical modifications
• Careful sequence selection
• Tissue-specific delivery

Long-Term Safety

• Chronic dosing considerations
• Accumulation effects
• Immune tolerance
• Carcinogenicity monitoring

Competitive Landscape

Major Players

| Company | Technology | Focus | Stage |
|---------|------------|-------|-------|
| Ionis | 2'-MOE ASO | Tau, amyloid | Phase 2 |
| Biogen | Partnership | Tau | Phase 2 |
| Alnylam | GalNAc-siRNA | APP | Phase 1 |
| Wave | Stereopure ASO | Tau, amyloid | Phase 1 |
| Arrowhead | TRiM-siRNA | Tau | Preclinical |

Emerging Companies

NeuBase Therapeutics:

• PAT-siRNA technology
• Peptide-acquired delivery
• Preclinical tau program

• RNA aptamer platform
• RUT-001 (tau)
• Preclinical

Academic/Research Programs

• Multiple academic groups developing novel ASOs
• University technology transfer programs
• Foundation-funded research

Market Analysis

Market Size

Current:

• $500M (2024) - AD RNA therapeutics
• Growth driven by clinical trial results

• $5B+ by 2035 (with approvals)
• Significant premium pricing potential

Pricing Expectations

• $50,000-150,000/year for CNS ASOs
• Similar range for siRNA therapeutics
• Premium for disease-modifying effects

Reimbursement Considerations

• Medicare coverage for FDA-approved products
• Specialty pharmacy distribution
• Prior authorization requirements

Pipeline Outlook

Near-term (2025-2027)

• BIIB080 Phase 2/3 results
• ALN-APP Phase 1/2 data
• Additional IND filings expected

Mid-term (2028-2030)

• First potential approvals
• Combination therapy trials
• Earlier-stage intervention

Long-term (2030+)

• Prevention trials in preclinical AD
• Personalized RNA therapeutics
• Regenerative approaches

Conclusion

RNA-based therapeutics represent a transformative approach to Alzheimer's disease treatment, offering the potential to directly target disease-causing genetic and molecular pathways. While significant challenges remain, particularly in CNS delivery, the clinical progress being made by multiple companies is encouraging.

The field has advanced considerably from early preclinical work to multiple clinical-stage programs targeting amyloid, tau, and neuroinflammation. With continued investment and successful clinical trials, RNA therapeutics could become a cornerstone of AD treatment in the coming decade[@smith2023][@chen2024].